Pharmaceutical - Novartis

Filter

Current filters:

Novartis

Popular Filters

1 to 25 of 353 results

Top 30 Pharmas spent $112 billion on R&D in 2013; report

Top 30 Pharmas spent $112 billion on R&D in 2013; report

17-12-2014

The world’s leading 30 pharmaceutical companies spent a combined $112 billion on research and development…

FinancialGlobalGlobalDataJohnson & JohnsonNovartisPfizerPharmaceuticalPharmaceutical sciencesResearch

Novartis gains US FDA approval of Signifor for acromegaly

Novartis gains US FDA approval of Signifor for acromegaly

16-12-2014

The US Food and Drug Administration has approved Swiss pharma giant Novartis’ Signifor (pasireotide)…

NovartisPharmaceuticalRare diseasesRegulationSigniforUSA

Added benefit of Eylea over Lucentis in DME not proven, says IQWiG

Added benefit of Eylea over Lucentis in DME not proven, says IQWiG

16-12-2014

The German Institute for Quality and Efficiency in Health Care (IQWiG) has compared trial data on German…

BayerEyleaGermanyLucentisNovartisOphthalmicsPharmaceuticalPricingRegulationRoche

Novartis' Cosentyx demonstrates superiority to Stelara in head-to-head psoriasis study

Novartis' Cosentyx demonstrates superiority to Stelara in head-to-head psoriasis study

15-12-2014

Swiss drug major Novartis announced that the Phase IIIb CLEAR study for Cosentyx (secukinumab) met its…

CosentyxDermatologicalsNovartisPharmaceuticalResearchSwitzerland

Novartis' Afinitor trial does not demonstrate statistical significance in HER2-positive breast cancer

Novartis' Afinitor trial does not demonstrate statistical significance in HER2-positive breast cancer

15-12-2014

Novartis announced that its BOLERO-1 trial of Afinitor (everolimus) in combination with Herceptin (trastuzumab)…

AfinitorHerceptinNovartisNovartis OncologyOncologyPaclitaxelPharmaceuticalResearchSwitzerland

EMA committee concludes no evidence Fluad caused deaths

EMA committee concludes no evidence Fluad caused deaths

04-12-2014

The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has concluded that…

EuropeFluadNovartisPharmaceuticalRegulationVaccines

Novartis’ fingolimod fails to meet endpoint in primary progressive multiple sclerosis study

Novartis’ fingolimod fails to meet endpoint in primary progressive multiple sclerosis study

01-12-2014

Swiss drug major Novartis’ has announced that its Phase III INFORMS study in primary progressive multiple…

CNS DiseasesfingolimodGilenyaNovartisPharmaceuticalResearchSwitzerland

Two batches of Novartis' Fluad taken off market for investigation in Italy after 13 deaths

Two batches of Novartis' Fluad taken off market for investigation in Italy after 13 deaths

01-12-2014

The Italian Medicines Agency (AIFA) has suspended two batches of Swiss drug major Novartis’ Fluad seasonal…

Anti-viralsFluadItalian Medicines AgencyItalyNovartisPharmaceuticalRegulation

Novartis’ heart failure drug LCZ696 granted accelerated assessment by CHMP

Novartis’ heart failure drug LCZ696 granted accelerated assessment by CHMP

28-11-2014

Swiss drug major Novartis announced that the European Medicines Agency’s Committee for Medicinal Products…

Cardio-vascularEuropeLCZ696NovartisPharmaceuticalRegulation

FTC puts conditions on GSK/Novartis consumer JV

27-11-2014

The US Federal Trade Commission has voted to approve UK pharma giant GlaxoSmithKline’s proposed acquisition…

Dr Reddy's LaboratoriesGlaxoSmithKlineHabitrolMergers & AcquisitionsNicodermNovartisPharmaceuticalRegulationUSAVaccines

Global oncology market to hit $109 billion in 2020

Global oncology market to hit $109 billion in 2020

26-11-2014

Cancer, with a death toll exceeding that of AIDS (acquired immune deficiency syndrome), tuberculosis…

AvastinCelgene Corp.GlobalMarkets & MarketingMergers & AcquisitionsNovartisOncologyPharmaceuticalResearchRevlimidRoche

NICE updated guidance backs Novartis’ Glivec for GIST

26-11-2014

UK health costs watchdog the National Institute for Health and Care Excellence (NICE) has issued final…

GlivecNovartisOncologyPharmaceuticalPricingRegulationUK

Novartis' Signifor approved in EU for acromegaly patients

Novartis' Signifor approved in EU for acromegaly patients

25-11-2014

The European Commission has approved Swiss drug major Novartis’ Signifor (pasireotide) for patients…

NovartisPharmaceuticalRare diseasesRegulationSigniforSwitzerland

US FDA pushes back decision date for Novartis’ panobinostat

US FDA pushes back decision date for Novartis’ panobinostat

25-11-2014

The US Food and Drug Administration has extended its priority review period by up to three months for…

FarydakNovartisOncologypanobinostatPharmaceuticalRegulationUSA

Future bleak for Novartis’ panobinostat in relapsed/refractory multiple myeloma, says analyst

21-11-2014

The vote against the recommendation that the US Food and Drug Administration approves Novartis’ panobinostat…

daratumumabelotuzumabFarydakNovartisOncologypanobinostatPharmaceuticalRegulation

NICE seeks more information on Xolair to treat hives

19-11-2014

UK health costs watchdog the National Institute for Health and Care Excellence (NICE) is calling on Swiss…

DermatologicalsNovartisPharmaceuticalPricingRegulationUKXolair

Novartis’ LCZ696 reduces the risk of dying and hospitalizations

Novartis’ LCZ696 reduces the risk of dying and hospitalizations

18-11-2014

New data on Swiss drug major Novartis’ investigational medicine LCZ696, for patients with heart failure…

Cardio-vascularLCZ696NovartisPharmaceuticalResearchSwitzerland

Novartis announces positive results for secukinumab in psoriatic arthritis

Novartis announces positive results for secukinumab in psoriatic arthritis

17-11-2014

Swiss drug major Novartis has announced results from the pivotal Phase III FUTURE 1 and FUTURE 2 studies…

Anti-Arthritics/RheumaticsNovartisPharmaceuticalResearchsecukinumabSwitzerland

Scottish backing for Novartis’ Afinitor for kidney cancer patients

Scottish backing for Novartis’ Afinitor for kidney cancer patients

10-11-2014

The Scottish Medicines Consortium has issued a positive recommendation for Swiss pharma major Novartis’…

AfinitorClinical pharmacologyHealthHealth Medical PharmaNHSNovartisOncologyPharmaceuticalPricingRegulationUK

FDA advisory panel votes against approval of Novartis MM drug

07-11-2014

At a meeting yesterday, the US Food and Drug Administration's Oncologic Drugs Advisory Committee (ODAC)…

LBH589NovartisOncologypanobinostatPharmaceuticalRegulationUSA

Genmab transfers its ofatumumab collaboration from GSK to Novartis

Genmab transfers its ofatumumab collaboration from GSK to Novartis

03-11-2014

Danish biotech company Genmab has entered into an agreement with UK pharma major GlaxoSmithKline and…

DenmarkGenmabGSKNovartisOfatumumab InjectionOncologyPharmaceuticalResearch

India’s Cipla calls for revocation of Novartis’ Onbrez patents

01-11-2014

Indian drugmaker Cipla has asked the government to revoke five patents that Swiss pharma major Novartis…

CiplaIndiaMarkets & MarketingNovartisOnbrezPatentsPharmaceuticalRespiratory and PulmonaryUnibrez

Novartis’ strong third-qtr boosted by sale of Idenix stake

Novartis’ strong third-qtr boosted by sale of Idenix stake

28-10-2014

Swiss pharma major Novartis this morning reported that sales for the third quarter of 2014 rose 4% to…

AlconFinancialNovartisPharmaceuticalSandozSwitzerland

CSL buys Novartis’ influenza vaccines business for $275 million

CSL buys Novartis’ influenza vaccines business for $275 million

27-10-2014

Swiss pharma major Novartis has agreed to divest its influenza vaccines business to Australia’s CSL…

Anti-viralsbioCSLCSL LimitedFinancialMergers & AcquisitionsNovartisPharmaceuticalVaccines

1 to 25 of 353 results

Back to top